Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 31;14(1):1-6.
doi: 10.21037/tcr-24-1737. Epub 2025 Jan 21.

The heterogeneity in oligoprogression and stereotactic body radiation therapy

Takafumi Hayashi  1 , Nagio Takigawa  2
Affiliations
Editorial

The heterogeneity in oligoprogression and stereotactic body radiation therapy

Takafumi Hayashi et al. Transl Cancer Res. .
No abstract available

Keywords: Oligoprogressive disease (OPD); metastasis-directed therapy (MDT); oligometastatic disease (OMD); stereotactic ablative radiotherapy; stereotactic body radiation therapy (SBRT).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1737/coif). N.T. has received grants (Eli Lilly Japan, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer-Ingelheim Japan, Ono Pharmaceutical, Kyowa Hakko Kirin, Nippon Kayaku Co. Ltd.) and personal fees (Eli Lilly Japan, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer-Ingelheim Japan, Ono Pharmaceutical, MSD, Bristol-Myers Squibb Company Japan) outside the submitted work. The other author has no conflicts of interest to declare.

Comment on

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. 10.1200/JCO.1995.13.1.8 - DOI - PubMed
    1. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020;21:e18-28. 10.1016/S1470-2045(19)30718-1 - DOI - PubMed
    1. Tsai CJ. Moving Away From Counting the Numbers: Leveraging a Sensible Clinical Trial Design for Oligometastatic Disease and Beyond. Int J Radiat Oncol Biol Phys 2022;114:846-8. 10.1016/j.ijrobp.2022.09.057 - DOI - PubMed
    1. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol 2020;148:157-66. 10.1016/j.radonc.2020.04.003 - DOI - PubMed
    1. Mimori K, Saito T, Niida A, et al. Cancer evolution and heterogeneity. Ann Gastroenterol Surg 2018;2:332-8. 10.1002/ags3.12182 - DOI - PMC - PubMed

LinkOut - more resources